"10.1371_journal.pone.0097666","plos one","2014-05-15T00:00:00Z","Francisco R Saenz; Virginie Ory; Maram AlOtaiby; Sonia Rosenfield; Mary Furlong; Luciane R Cavalli; Michael D Johnson; Xuefeng Liu; Richard Schlegel; Anton Wellstein; Anna T Riegel","Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States of America; Department of Pathology, Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States of America","Conceived and designed the experiments: AR XL RS AW. Performed the experiments: FS VO LC. Analyzed the data: MA SR MF LC MJ AR AW FS. Contributed reagents/materials/analysis tools: MJ XL RS. Contributed to the writing of the manuscript: FS VO MA SR MF LC MJ AR XL RS AW.","Georgetown University has a patent pending on the cell reprogramming technology (Immortalizing Epithelial Cells and Methods of Use, Application No. 13/885,078) and has licensed the technology to a new biotechnology company, Propagenix (www.propagenix.com). Georgetown University also has founding equity in Propagenix. RS and XL are Professors at Georgetown University who are consultants to Propagenix and RS has founding equity in the company. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","05","Francisco R Saenz","FRS",11,TRUE,4,3,8,NA,TRUE,TRUE,FALSE,0,NA,FALSE
